Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time

Helena Enocsson, Tanja Lukic, Michael Ziegelasch, Alf Kastbom

Translational research · 2021 · 21 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and disease outcome in various diseases. In rheumatoid arthritis (RA), suPAR have shown an association with inflammation and swollen joints, but data on suPAR in relation to early disease course and disease progression are lacking. This study investigates the potential of suPAR to predict or reflect disease outcome in early RA. Serum suPAR was measured by enzyme-linked immunosorbent assay at disease onset and after 3 and 36 months in 252 patients from a Swedish prospective observational early RA cohort. Levels and changes of suPAR were analyzed in relation to the 28-joint disease activity score (DAS28) and joint damage according to the Larsen score at inclusion and during follow-up. 100 healthy blood donors served as controls. Circulating levels of suPAR were higher in RA patients at all time points as compared to healthy controls. Baseline suPAR was significantly associated with baseline disease activity whereas suPAR levels at 36 months were associated with joint damage at 36 months. No predictive value of suPAR levels or changes in suPAR levels over time were found. In conclusion, suPAR levels associate with disease activity in early untreated RA and reflects joint damage at later stages. Increased suPAR in established RA could indicate patients in need of frequent monitoring of joint status, irrespective of disease activity. In the view of suPAR as a rapidly emerging biomarker, it is important to be aware of its ability to reflect both inflammation and subsequent damage. Soluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and disease outcome in various diseases. In rheumatoid arthritis (RA), suPAR have shown an association with inflammation and swollen joints, but data on suPAR in relation to early disease course and disease progression are lacking. This study investigates the potential of suPAR to predict or reflect disease outcome in early RA. Serum suPAR was measured by enzyme-linked immunosorbent assay at disease onset and after 3 and 36 months in 252 patients from a Swedish prospective observational early RA cohort. Levels and changes of suPAR were analyzed in relation to the 28-joint disease activity score (DAS28) and joint damage according to the Larsen score at inclusion and during follow-up. 100 healthy blood donors served as controls. Circulating levels of suPAR were higher in RA patients at all time points as compared to healthy controls. Baseline suPAR was significantly associated with baseline disease activity whereas suPAR levels at 36 months were associated with joint damage at 36 months. No predictive value of suPAR levels or changes in suPAR levels over time were found. In conclusion, suPAR levels associate with disease activity in early untreated RA and reflects joint damage at later stages. Increased suPAR in established RA could indicate patients in need of frequent monitoring of joint status, irrespective of disease activity. In the view of suPAR as a rapidly emerging biomarker, it is important to be aware of its ability to reflect both inflammation and subsequent damage. AT A GLANCE COMMENTARYEnocsson H, et al.BackgroundSoluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and outcome in various diseases. Herein, suPAR in serum was evaluated over time in recent-onset rheumatoid arthritis (RA).Translational SignificancesuPAR correlated with disease activity at baseline, whereas follow-up levels associated with structural joint damage. Thus, increased suPAR in patients with established RA may reflect joint destruction. Due to the emerging interest in suPAR as a prognostic biomarker, it is important to acknowledge that suPAR may reflect different aspects of disease depending on disease duration.IntroductionThe membrane-bound urokinase plasminogen activator receptor (uPAR; CD87) is a multi-ligand receptor encoded by the PLAUR gene and expressed on endothelial cells, smooth muscle cells, fibroblasts and immune cells such as neutrophils and monocytes.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar The receptor and its soluble form suPAR, is involved in processes like proteolysis, tissue remodeling, cell migration and inflammation via interaction with its ligand urokinase plasminogen activator (uPA; also known as urokinase), and lateral interactions with other receptors such as integrins, vitronectin and formyl peptide receptors.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar, 2de Paulis A Montuori N Prevete N et al.Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.J Immunol. 2004; 173: 5739-5748Crossref PubMed Scopus (100) Google Scholar, 3Kanse SM Kost C Wilhelm OG Andreasen PA Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.Exp Cell Res. 1996; 224: 344-353https://doi.org/10.1006/excr.1996.0144Crossref PubMed Scopus (232) Google ScholarIncreased uPAR expression and circulating suPAR levels were initially described as prognostic factors in various forms of malignancies and has later been described as a marker of immune activation, disease severity and prognosis in multiple inflammatory and infectious diseases.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar,4Enocsson H Wetterö J Skogh T Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.Transl Res. 2013; 162: 287-296https://doi.org/10.1016/j.trsl.2013.07.003Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar, 5Sjöwall C Martinsson K Cardell K Ekstedt M Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.Transl Res. 2015; 165: 658-666https://doi.org/10.1016/j.trsl.2014.09.007Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar, 6Andersen O Eugen-Olsen J Kofoed K Iversen J Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.J Med Virol. 2008; 80: 209-216https://doi.org/10.1002/jmv.21114Crossref PubMed Scopus (105) Google Scholar, 7Ostrowski SR Ullum H Goka BQ et al.Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.J Infect Dis. 2005; 191: 1331-1341https://doi.org/10.1086/428854Crossref PubMed Scopus (67) Google Scholar, 8Enocsson H Wirestam L Dahle C et al.Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.J Autoimmun. 2020; 106102340https://doi.org/10.1016/j.jaut.2019.102340Crossref PubMed Scopus (20) Google ScholarRheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and subsequent damage to bone and cartilage, but also systemic inflammation, fatigue, increased risk of cardiovascular disease and other extra-articular manifestations.9Scott DL Wolfe F Huizinga TW. Rheumatoid arthritis.Lancet. 2010; 376: 1094-1108https://doi.org/10.1016/S0140-6736(10)60826-4Abstract Full Text Full Text PDF PubMed Scopus (2311) Google Scholar The measurement of anti‐citrullinated protein antibodies (ACPA) is a diagnostic tool and their presence associates with an increased risk of early erosions and extra-articular manifestations.10Willemze A Trouw LA Toes RE Huizinga TW. The influence of ACPA status and characteristics on the course of RA.Nat Rev. 2012; 8: 144-152https://doi.org/10.1038/nrrheum.2011.204Crossref Scopus (149) Google Scholar Other than presence of ACPA, only a limited number of biomarkers have shown potential to prognosticate disease progression in RA.11Mahler M Martinez-Prat L Sparks JA Deane KD. Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease.Autoimmun Rev. 2020; 19102506https://doi.org/10.1016/j.autrev.2020.102506Crossref PubMed Scopus (24) Google ScholarA few previous studies have investigated circulating suPAR in rheumatoid arthritis.12Slot O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google Scholar, et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar, T A et al.Soluble urokinase plasminogen activator receptor as a biomarker to predict the to in patients with rheumatoid arthritis in a Google Scholar In circulating levels of suPAR were increased in patients compared to healthy O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google Scholar, et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar, T A et al.Soluble urokinase plasminogen activator receptor as a biomarker to predict the to in patients with rheumatoid arthritis in a Google Scholar and correlated with the number of swollen O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar also patients with limited disease et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar of the studies early a of to in to future joint damage and et for the of rheumatoid arthritis with and Rheum Dis. 2020; PubMed Scopus Google Scholar to the potential of serum suPAR as a biomarker of disease progression in recent-onset and and were in a Swedish prospective observational early RA has been described in K A A Skogh and peptide associate with whereas associates with in patients with recent-onset rheumatoid arthritis Swedish Immunol. PubMed Scopus Google Scholar In patients with months the of or a clinical RA on joint arthritis and were and K A A Skogh and peptide associate with whereas associates with in patients with recent-onset rheumatoid arthritis Swedish Immunol. PubMed Scopus Google Scholar Serum and clinical were at inclusion and at and 36 months of follow-up. Larsen score was at inclusion and at the 36 months follow-up In 252 patients were analyzed for serum suPAR at time points 3 and 36 and 3 months were to the of the disease changes in disease activity are to were studied at 36 to the blood at the Baseline characteristics are shown in characteristics of the 252 early rheumatoid arthritis or number for for The patients were as of for epitope for for ACPA, protein activity rheumatoid for for The patients were as of for for for in a ACPA was analyzed by on the with as Rheumatoid were by according to clinical at the epitope are described K Martinsson K M et antibodies in early rheumatoid arthritis associate with inflammatory activity and PubMed Scopus Google healthy blood donors served as blood was from at Serum was and at study was in with the of was from all The study was by the in patients were with of 28-joint disease activity that and in a prospective study of patients with rheumatoid PubMed Scopus Google Scholar protein joint damage according to the Larsen to Larsen score in of rheumatoid arthritis in Google Scholar and A progression score was by the Larsen score at baseline from the Larsen score at the 36 months follow-up was measured the uPAR enzyme-linked immunosorbent assay This a an on of the suPAR and is with a the potential of the of rheumatoid with suPAR in the suPAR was in and suPAR from the uPAR was in different concentrations to the serum and the was analyzed by the The was and from patients and were or and analyzed as according to at and 3 months were on the to from the 36 months were analyzed from months and from all were according to an that was on of of assay than were and data from the are in data was measured at and data were in suPAR and a at all whereas Larsen number of swollen joints, number of and progression were or was to suPAR and in and The was to suPAR levels the patients at the different time was the was all with patients and with Larsen score or progression were with were evaluated for were by the of of the of value and and and by of of P value than was were or levels and characteristics over suPAR levels patients significantly all analyzed with the suPAR levels 3 months after inclusion and the at 36 months suPAR levels were significantly higher in RA patients at all compared to healthy and significantly inclusion and months of suPAR, and Larsen score over time are shown in were in suPAR levels and patients at the higher suPAR levels compared to P A and baseline suPAR was for the patients P but baseline levels of suPAR were in ACPA patients compared with ACPA patients P and levels of ACPA a with baseline suPAR P No in suPAR levels was and in baseline suPAR was on significantly higher suPAR levels at 3 months compared with the patients status was P as as compared with P Levels of suPAR were also increased at 36 months compared with the patients P or P epitope or significantly suPAR levels at compared to patients of suPAR and in RA were serum suPAR levels at all clinical Larsen score and progression over 3 at the were suPAR and at baseline as as suPAR and Larsen score at 36 months also baseline suPAR and baseline the patients with data and a as for the of patients changes in suPAR and 3 and 36 months as as 3 and 36 months were correlated with clinical outcome but with a were baseline suPAR or 3 months suPAR with 36 months Larsen score or patients as according to and Larsen at baseline and 36 months The with the baseline significantly higher suPAR levels at In patients with Larsen score at 36 months higher levels of suPAR at 36 months compared to patients with Larsen score No in suPAR were on Larsen score at baseline or at 36 levels in according to disease activity and damage. Baseline suPAR and its association with baseline 28-joint disease activity score Baseline suPAR at different baseline damage 36 months suPAR levels at different disease activity. suPAR and its association with Larsen and indicate and suPAR and clinical are of and association suPAR and at baseline was in suPAR levels at baseline according to ACPA status, an with suPAR and ACPA was that suPAR was associated with of ACPA status with potential on was by in a ACPA and with as the for the association suPAR and only was significantly associated with the on an was with and suPAR as a of both and suPAR on was of the in a for suPAR in all ACPA, anti‐citrullinated protein 28-joint disease activity months suPAR, soluble urokinase plasminogen activator was of the in a for suPAR in all in a 36 suPAR was associated with Larsen score at 36 months. Larsen score was a score to with and suPAR as but data on both and Larsen was only for associated with Larsen score at 36 months were by to a status and whereas and ACPA were associated with Larsen score with suPAR and as the for suPAR ACPA and also a on Larsen score at 36 data were for patients of also Larsen score data at 36 ACPA, anti‐citrullinated protein months 36 suPAR, soluble urokinase plasminogen activator data were for patients of also Larsen score data at 36 months. in a is the study to suPAR as a prognostic biomarker in recent-onset RA. suPAR levels in untreated recent-onset RA in association with disease and levels during 3 months of early The association with disease activity at baseline is in with previous on established O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar but levels during the 3 months is as disease activity during the In a study by et baseline suPAR levels were to outcome patients with established RA. patients as higher suPAR levels in with disease T A et al.Soluble urokinase plasminogen activator receptor as a biomarker to predict the to in patients with rheumatoid arthritis in a Google Scholar This may indicate a of increased suPAR levels that clinical studies on inflammatory other than RA have an association suPAR and subsequent organ H Wetterö J Skogh T Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.Transl Res. 2013; 162: 287-296https://doi.org/10.1016/j.trsl.2013.07.003Abstract Full Text Full Text PDF PubMed Scopus (39) Google C Martinsson K Cardell K Ekstedt M Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.Transl Res. 2015; 165: 658-666https://doi.org/10.1016/j.trsl.2014.09.007Abstract Full Text Full Text PDF PubMed Scopus (24) Google H Wirestam L Dahle C et al.Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.J Autoimmun. 2020; 106102340https://doi.org/10.1016/j.jaut.2019.102340Crossref PubMed Scopus (20) Google H Sjöwall C Wetterö J. Soluble urokinase plasminogen activator biomarker in systemic lupus 2015; PubMed Scopus Google Scholar, B T C Soluble urokinase plasminogen activator receptor is associated with liver fibrosis in C 2012; PubMed Scopus Google Scholar, T Eugen-Olsen J et al.Soluble urokinase plasminogen activator receptor is associated with organ damage and cardiovascular Full Text Full Text PDF PubMed Scopus Google Scholar joint damage could be as the RA to organ and of rheumatoid arthritis: a PubMed Scopus Google Scholar to its relation to suPAR In to disease association suPAR and damage at suPAR levels at the follow-up associated with damage. A previous study on established RA an association suPAR and joint the in that study were of the clinical care and O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google be that the in the study is from compared to the in other studies from may the ability to of suPAR and as as the of suPAR in with increased blood and J and of soluble urokinase plasminogen activator receptor (suPAR) in healthy PubMed Scopus Google Scholar The assay from is a suPAR and whereas the from a but a a a suPAR assay from uPAR and the from higher levels of suPAR and of disease the was disease and healthy were by both et and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in and of PubMed Scopus Google presence of ACPA is a risk for progression in RA is also in the M A Martinsson K et peptide antibodies are associated with damage but disease activity in early rheumatoid arthritis in J 2020; PubMed Scopus Google Scholar it is that suPAR levels are in ACPA patients at baseline, suPAR at reflects joint damage. is a in RA that ACPA patients have higher disease activity at the time of compared to ACPA the association suPAR and disease activity also after for is known that ACPA RA have and risk factors compared to ACPA A Skogh T L et with and epitope and antibodies to in early rheumatoid 2015; PubMed Scopus Google Scholar and suPAR is a of the of study the follow-up a for of suPAR in relation to structural joint damage. the association and suPAR at baseline also only patients with is also a of disease changes in suPAR over time with other rheumatic or inflammatory a suPAR disease activity and damage in a inflammatory suPAR associates with RA disease activity but and clinical suPAR reflects structural joint damage. are important for studies on suPAR also in other than the need for The data an clinical value of suPAR for prognostic in early RA conclusion, suPAR levels are 3 of early RA with disease activity and structural joint damage over Thus, is important suPAR as a biomarker in inflammatory diseases. AT A GLANCE COMMENTARYEnocsson H, et al.BackgroundSoluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and outcome in various diseases. Herein, suPAR in serum was evaluated over time in recent-onset rheumatoid arthritis (RA).Translational SignificancesuPAR correlated with disease activity at baseline, whereas follow-up levels associated with structural joint damage. Thus, increased suPAR in patients with established RA may reflect joint destruction. Due to the emerging interest in suPAR as a prognostic biomarker, it is important to acknowledge that suPAR may reflect different aspects of disease depending on disease H, et al.BackgroundSoluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and outcome in various diseases. Herein, suPAR in serum was evaluated over time in recent-onset rheumatoid arthritis (RA).Translational SignificancesuPAR correlated with disease activity at baseline, whereas follow-up levels associated with structural joint damage. Thus, increased suPAR in patients with established RA may reflect joint destruction. Due to the emerging interest in suPAR as a prognostic biomarker, it is important to acknowledge that suPAR may reflect different aspects of disease depending on disease H, et urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and outcome in various diseases. Herein, suPAR in serum was evaluated over time in recent-onset rheumatoid arthritis Soluble urokinase plasminogen activator receptor (suPAR) is intensively studied as a biomarker of inflammation and outcome in various diseases. Herein, suPAR in serum was evaluated over time in recent-onset rheumatoid arthritis SignificancesuPAR correlated with disease activity at baseline, whereas follow-up levels associated with structural joint damage. Thus, increased suPAR in patients with established RA may reflect joint destruction. Due to the emerging interest in suPAR as a prognostic biomarker, it is important to acknowledge that suPAR may reflect different aspects of disease depending on disease suPAR correlated with disease activity at baseline, whereas follow-up levels associated with structural joint damage. Thus, increased suPAR in patients with established RA may reflect joint destruction. Due to the emerging interest in suPAR as a prognostic biomarker, it is important to acknowledge that suPAR may reflect different aspects of disease depending on disease membrane-bound urokinase plasminogen activator receptor (uPAR; CD87) is a multi-ligand receptor encoded by the PLAUR gene and expressed on endothelial cells, smooth muscle cells, fibroblasts and immune cells such as neutrophils and monocytes.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar The receptor and its soluble form suPAR, is involved in processes like proteolysis, tissue remodeling, cell migration and inflammation via interaction with its ligand urokinase plasminogen activator (uPA; also known as urokinase), and lateral interactions with other receptors such as integrins, vitronectin and formyl peptide receptors.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar, 2de Paulis A Montuori N Prevete N et al.Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.J Immunol. 2004; 173: 5739-5748Crossref PubMed Scopus (100) Google Scholar, 3Kanse SM Kost C Wilhelm OG Andreasen PA Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.Exp Cell Res. 1996; 224: 344-353https://doi.org/10.1006/excr.1996.0144Crossref PubMed Scopus (232) Google ScholarIncreased uPAR expression and circulating suPAR levels were initially described as prognostic factors in various forms of malignancies and has later been described as a marker of immune activation, disease severity and prognosis in multiple inflammatory and infectious diseases.1Thuno M Macho B Eugen-Olsen J. suPAR: the molecular crystal ball.Disease Markers. 2009; 27: 157-172https://doi.org/10.3233/DMA-2009-0657Crossref PubMed Scopus (370) Google Scholar,4Enocsson H Wetterö J Skogh T Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.Transl Res. 2013; 162: 287-296https://doi.org/10.1016/j.trsl.2013.07.003Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar, 5Sjöwall C Martinsson K Cardell K Ekstedt M Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.Transl Res. 2015; 165: 658-666https://doi.org/10.1016/j.trsl.2014.09.007Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar, 6Andersen O Eugen-Olsen J Kofoed K Iversen J Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.J Med Virol. 2008; 80: 209-216https://doi.org/10.1002/jmv.21114Crossref PubMed Scopus (105) Google Scholar, 7Ostrowski SR Ullum H Goka BQ et al.Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.J Infect Dis. 2005; 191: 1331-1341https://doi.org/10.1086/428854Crossref PubMed Scopus (67) Google Scholar, 8Enocsson H Wirestam L Dahle C et al.Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.J Autoimmun. 2020; 106102340https://doi.org/10.1016/j.jaut.2019.102340Crossref PubMed Scopus (20) Google ScholarRheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and subsequent damage to bone and cartilage, but also systemic inflammation, fatigue, increased risk of cardiovascular disease and other extra-articular manifestations.9Scott DL Wolfe F Huizinga TW. Rheumatoid arthritis.Lancet. 2010; 376: 1094-1108https://doi.org/10.1016/S0140-6736(10)60826-4Abstract Full Text Full Text PDF PubMed Scopus (2311) Google Scholar The measurement of anti‐citrullinated protein antibodies (ACPA) is a diagnostic tool and their presence associates with an increased risk of early erosions and extra-articular manifestations.10Willemze A Trouw LA Toes RE Huizinga TW. The influence of ACPA status and characteristics on the course of RA.Nat Rev. 2012; 8: 144-152https://doi.org/10.1038/nrrheum.2011.204Crossref Scopus (149) Google Scholar Other than presence of ACPA, only a limited number of biomarkers have shown potential to prognosticate disease progression in RA.11Mahler M Martinez-Prat L Sparks JA Deane KD. Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease.Autoimmun Rev. 2020; 19102506https://doi.org/10.1016/j.autrev.2020.102506Crossref PubMed Scopus (24) Google ScholarA few previous studies have investigated circulating suPAR in rheumatoid arthritis.12Slot O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google Scholar, et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar, T A et al.Soluble urokinase plasminogen activator receptor as a biomarker to predict the to in patients with rheumatoid arthritis in a Google Scholar In circulating levels of suPAR were increased in patients compared to healthy O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google Scholar, et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar, T A et al.Soluble urokinase plasminogen activator receptor as a biomarker to predict the to in patients with rheumatoid arthritis in a Google Scholar and correlated with the number of swollen O Brunner N Locht H Oxholm P Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.Ann Rheum Dis. 1999; PubMed Scopus Google et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar also patients with limited disease et al.Soluble urokinase plasminogen activator receptor (suPAR) in the of inflammatory activity of rheumatoid arthritis patients in 2013; PubMed Scopus Google Scholar of the studies early a of to in to future joint damage and et for the of rheumatoid arthritis with and Rheum Dis. 2020; PubMed Scopus Google Scholar to the potential of serum suPAR as a biomarker of disease progression in recent-onset RA.

References

23